{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/macular-degeneration-age-related/background-information/definition/","result":{"pageContext":{"chapter":{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field 666e3839-a733-4c9a-b8d8-2182a335e010 --><h2>What is it?</h2><!-- end field 666e3839-a733-4c9a-b8d8-2182a335e010 -->","summary":"","htmlStringContent":"<!-- begin item 406beccc-4c09-4760-b66e-3de97471b125 --><!-- begin field ed581662-8d64-4b95-acf8-8f6bebeb5bf4 --><ul><li><strong>Age-related macular degeneration (AMD) is a potentially progressive disorder of the macula that typically affects people aged over 50 years </strong>— it is the commonest cause of severe irreversible visual impairment in older adults in the developed world.</li><li><strong>AMD is characterized by the presence of one or more of the following:</strong><br><ul><li>Drusen — at least intermediate drusen (63 micrometres or more in diameter). These may be visible on ophthalmoscopy as pale yellow spots on the retina. <ul><li>Drusen are collections of lipid material that accumulate beneath the retinal pigment epithelium (RPE) and within Bruch’s membrane. </li></ul></li><li>RPE abnormalities — areas of hypopigmentation or hyperpigmentation.</li><li>Geographic atrophy — breakdown of light-sensitive cells in the macula causes one or more sharply demarcated areas of partial or complete depigmentation (atrophy) of the RPE. The areas of atrophy can enlarge over time. Atrophy may or may not involve the fovea (the central part of the macula). </li><li>Choroidal neovascularization ([CNV] also called exudative, or wet disease) — the development of new blood vessels in the choroid. CNV breaches the normal anatomical barrier of Bruch’s membrane and invades the subpigment epithelial and or subretinal spaces. <ul><li>The new vessels are unlike normal retinal vessels and easily bleed or leak blood constituents, resulting in distortion and scarring of the retina.</li></ul></li><li>Polypoidal choroidal vasculopathy (PCV) — characterized by multiple and recurrent serosanguineous RPE detachments. </li><li>Reticular pseudodrusen (also referred to as subretinal drusenoid deposits). </li><li>Retinal angiomatous proliferation — characterized by proliferation of retinal capillaries in the paramacular area that may present as intraretinal, subretinal, or CNV.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Royal College of Ophthalmologists, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>]</p><!-- end field ed581662-8d64-4b95-acf8-8f6bebeb5bf4 --><!-- end item 406beccc-4c09-4760-b66e-3de97471b125 -->","topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","lastRevised":"Last revised in October 2020","chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","fullItemName":"Management","slug":"management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}